Related Experiment Video
Updated: Feb 16, 2026

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
Published on: December 5, 2017
[Screening the differential expression of adriamycin-resistance related genes of breast cancer by cDNA microarray]
Hao Peng1, Hua-Wei Yang, Li-Wei Song
1Department of General Surgery Oncology, General Coal Hospital, Beijing 100028, China. penghao009@sina.com
Objective:
To study the differential gene expression of adriamycin-resistance of breast cancer cell line MCF-7/ADR as compared with its parent cell MCF-7 and screen the related genes.
Methods:
The in vitro inhibitory rate of MCF-7/ADR and MCF-7 cell lines to ADM (adriamycin) was examined by MIT assay. Then a cDNA microarray representing 14,755 genes was used to analyze the expression profiles of these two breast cancer cell lines.
Results:
The inhibitory rate of MCF-7/ ADR to ADM was lower than that of MCF-7(P <0.05)and the drug resistance to ADR of MCF-7/ADR was stronger than that of MCF-7. There were 2374 differential expression genes in MCF-7/adr and MCF-7 cell lines, of which 1099 genes upregulated with 99 genes 10-fold upregulated and 1275 genes downregulated with 71 genes 10-fold downregulated. The important upregulated genes were Bcl-2, GSTP1, c-myc, MMP-1 and NNMT while those downregulated ones p53, p21, p27 and CYPIA1.
Conclusion:
Drug resistance of breast cancer is a complicated process involving the expression of many upregulated or downregulated genes. The application of gene chip in screening drug-resistant genes may be a new approach for selecting the optimal chemotherapeutic regimens. [Key words]
Insights
Breast cancer cells (MCF-7/ADR) exhibit increased adriamycin resistance compared to parent cells (MCF-7). Gene expression analysis revealed significant differences in numerous genes, including Bcl-2 and p53, impacting drug resistance.
Area of Science:
- Molecular Biology
- Genomics
- Cancer Research
Context:
- Breast cancer is a leading cause of mortality in women worldwide.
- Adriamycin (ADM) is a common chemotherapeutic agent used in breast cancer treatment.
- Acquired resistance to chemotherapy, such as ADM, significantly limits treatment efficacy.
Purpose:
- To investigate the differential gene expression profiles between adriamycin-resistant (MCF-7/ADR) and sensitive (MCF-7) breast cancer cell lines.
- To identify genes associated with adriamycin resistance in breast cancer.
- To explore the potential of gene expression profiling for guiding chemotherapy selection.
Summary:
- MCF-7/ADR cells demonstrated significantly lower sensitivity to ADM compared to MCF-7 cells, confirming enhanced drug resistance.
- Microarray analysis identified 2374 differentially expressed genes between the two cell lines.
- Key upregulated genes included Bcl-2, GSTP1, c-myc, MMP-1, and NNMT, while downregulated genes included p53, p21, p27, and CYPIA1.
Impact:
- This study highlights the complex genetic basis of adriamycin resistance in breast cancer.
- Identifying specific upregulated and downregulated genes provides potential therapeutic targets.
- Gene expression profiling offers a promising approach for personalizing breast cancer chemotherapy regimens.
Related Concept Videos
What is Gene Expression?
Gene expression is the process in which DNA directs the synthesis of functional products, that is, proteins. Cells can regulate gene expression at various stages. It allows organisms to generate different cell types and enables cells to adapt to internal and external factors.
Genetic Information Flows from DNA to RNA to Protein
A gene is a stretch of DNA that serves as the blueprint for functional RNAs and proteins. Since DNA is made up of nucleotides and proteins consist of amino...
What is Gene Expression?
Chromatin Position Affects Gene Expression
Topologically Associated Domains (TADs)
The 3-dimensional positioning of chromatin in the nucleus influences the...
Cell Specific Gene Expression
Cell Specific Gene Expression
Treatment Resistant Cancers

